Ann: Trading Halt, page-143

First 143 Last

Share
Profile

Follow
flex76

373 Posts.

20

04/11/21

13:01

Post #: 57313586
Share

Originally posted by samfiodiving: ↑

We were intially told some weeks ago that a draft opinion had been put forwards, and basically it had been approved along the lines of Anps expectancy or their implemented plans for the trial

So this final sitting was for the drsft approval

Or adoption by the EMA

Hence the trading halt

So my original thoughts were we would get 2 swipes at the market over this, i really wasn't expecting a TH for the decision as we were already aware of what was coming, barring the decision of course

But obviously there is going to be a huge amount of detail coming forwards from this hopefully approval for the 2b trial, as the Pidco sets the plans up for the drug basically going to market, so huge amount of info to come out of this and has obviously been deemed important enough to warrant a TH

So moving onto the partnering interest

Well don't think DD by any pharma has just started, this hopefull approval is not only what we have been waiting for but also one would imagine what any pharma interested would have been waiting for, so once this is official the trial has got the green light, then basically the interested party could finalise it's DD that the projected route to market was aligned with their thoughts and nothing is missing hence no roadblocks once the trial was complete and straight to market because all the i and t had been covered in this of pdco set up to market approval and sales of the drug

So next step is fingers crossed the pdco has been adopted by the EMA, and we are of to trial, the so called sell of doesn't bother me i wouldn't call it a sell off look where we have come from just recently 20c wasn't it and where is it sat now lol ,

I have said this previously, the only reason i am here is because i have faith in the pipeline and at this moment in time that faith remains this pipeline has not let me down thus far, with results put forwards one would think this would be a no brainer, but this does not mean that it's a given to say i am not apprehensive i think that would be an understatement lol

So GL to us all, get this out of the way then hopefully a partner will come onboard

Then i will start thinking along the lines that Vinc put out there a few days, as on moving forwards with ANP In my portfolio

EVERY DAY WILL BE A HAPPY DAY

I like it Vinc

GL to everyone especially the LTs here you know who you are

See how we go

Expand

Sam
Keen to hear ur thoughts on what has transpired ovee the last week or two????

ANP Price at posting: 23.3¢ Sentiment: Hold Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

OCC

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

MSB

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

SRL

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

SPR

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

PL3

Patagonia looks to raise $2.15M for South American exploration and development

There are more pages in this discussion • 1 more message in this thread...

First 143 Last

Add PER (ASX) to my watchlist

(20min delay)
Last 8.6¢		Change 0.001(1.18%)		Mkt cap ! $77.53M

Open	High	Low	Value	Volume
8.5¢	8.8¢	8.4¢	$18.63K	218.7K

Buyers (Bids)

No.	Vol.	Price($)
1	30000	8.5¢

Sellers (Offers)

Price($)	Vol.	No.
8.6¢	46681	1

View Market Depth

No.	Vol.	Price($)
1	30000	0.085
1	29206	0.083
2	96888	0.082
1	38100	0.081
4	217800	0.080

Price($)	Vol.	No.
0.086	46681	1
0.088	96794	4
0.089	135000	2
0.090	443317	5
0.091	108000	1

Last trade - 16.10pm 09/07/2024 (20 minute delay)

PER (ASX) Chart

Ann: Trading Halt, page-143

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

Patagonia looks to raise $2.15M for South American exploration and development

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Trading Halt, page-143

Top Stories

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

Patagonia looks to raise $2.15M for South American exploration and development

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News